Skip to main content
. 2024 Mar 6;25(5):3049. doi: 10.3390/ijms25053049

Table 1.

IC50 of different compounds in DDP-sensitive and -resistant HR-proficient and -deficient ID8 cells.

DRUG F3 F3 ddpR FI p Value * Brca1−/− Brca1−/− ddpR FI p Value *
CISPLATIN (µM) 16.94 ± 8.26 >150 >10 p = 0.003 3.88 ± 0.86 22.05 ± 11.63 5.7 p = 0.02
CARBOPLATIN (µM) 60.67 ± 9.08 1060 ± 176.64 17.5 p = 0.015 25.2 ± 0.35 86.7 ± 1.27 3.4 p = 0.002
OXALIPLATIN (µM) 79.08 ± 17.92 212 ± 82.72 2.7 p = 0.05 14.41 ± 2.18 32.55 ± 3.56 2.1 p = 0.0078
OLAPARIB (µM) 6.44 ± 0.5 7.53 ± 3.98 1.2 p = 0.63 0.08 ± 0.002 2.05 ± 0.7 24.5 p = 0.05
RUCAPARIB (µM) 13.68 ± 2.86 5.24 ± 2.63 0.4 p = 0.0197 0.21 ± 0.1 3.58 ± 1.71 17.3 p = 0.027
NIRAPARIB (µM) 0.35 ± 0.04 0.33 ± 0.3 0.9 p = 0.93 0.04 ± 0.01 0.26 ± 0.07 7.5 p = 0.043
YONDELIS (nM) 0.8 ± 0.36 1.95 ± 0.74 2.5 p = 0.18 0.11 ± 0.02 0.57 ± 0.04 5.2 p = 0.0056
PACLITAXEL (nM) 19.72 ± 2.31 4.18 ± 1.8 0.2 p = 0.017 22.27 ± 1.9 14.8 ± 3.1 0.7 p = 0.1
DOXORUBICIN (nM) 84.62 ± 7.01 44.2 ± 0.49 0.5 p = 0.01 34.8 ± 10.7 27.65 ± 0.2 0.8 p = 0.44
KU55933 (µM) 4.06 ± 0.59 2.42 ± 0.16 0.6 p = 0.06 1.66 ± 0.77 1.11 ± 0.18 0.7 p = 0.43
AZD6738 (µM) 0.26 ± 0.07 0.83 ± 0.65 3.2 p = 0.2 0.2 ± 0.04 0.23 ± 0.11 1.2 p = 0.64
AZD1775 (µM) 0.42 ± 0.2 1.08 ± 0.69 2.6 p = 0.11 0.2 ± 0.09 0.2 ± 0.14 0.9 p = 0.76
AZD7762 (µM) 0.19 ± 0.08 0.38 ± 0.17 2 p = 0.08 0.13 ± 0.06 0.22 ± 0.15 1.7 p = 0.28
NU7741 (µM) 1.72 ± 0.11 1.34 ± 0.07 0.8 p = 0.06 2.32 ± 0.11 1.02 ± 0.29 0.4 p = 0.03

FI: fold increase. * Unpaired t test.